Avance IVDr for prostate cancer profiling

Bruker’s Standardized nuclear magnetic resonance (NMR) spectroscopy platform allows affordable, high-performance NMR pre-clinical screening and IVD-by-NMR identification and validation (on RUO Level) of new NMR assays.

The latest AVANCE IVDr system, currently used for research purposes only, is a comprehensive, established and standardized platform not only for NMR pre-clinical research and screening but also for IVD-by-NMR research.

The platform delivers high-sensitivity and data-rich output at 600 MHz proton-NMR frequency while integrating advanced software, hardware, automation, spectral libraries and standard operating procedures (SOPs) for pre-clinical screening and high-performance biofluid assay validation.

The benefits for customers include greater data content and spectral feature differentiation than low-field NMR systems while also offering outstanding reproducibility, high throughput and possibly considerably lower cost per sample for improved preparation and support of clinical screening and IVD-by-NMR discovery and validation (on RUO level).

Other Equipment by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.